Maturing Biotechs Turn to Pharma's Markets  

Oleh:

Ratner, Mark

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 3 (Mar. 2005), page 269.
Topik: biotechnology; maturing biotech; pharma's market

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Pleased with sepracor's 2004 results and its anticipated launch in the first quarter of 2005 of one of biotech's rare mass market drugs, investors have bid up the firm's stock to near three year highs. Sepracor's focus on a primary care market is the latest example of a shift in strategy at certain maturing biotech companies to target broader, highly competitive markets traditionally served by big pharma. Three years ago, after receipt of a not approvable letter from the US food and drug administration on its allergy medication soltara, the active metabolite of the compound astemizole, marlborough, massachussets based sepracor was in the doldrums...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali